達那唑

達那唑（Danazol）為一種用於治療子宮內膜異位症、乳腺小叶增生、遺傳性血管性水腫（英语：hereditary angioedema）及其他疾病的藥物^{[8][1][10][11][12]}，主要經口服给药^[1]。

達那唑

臨床資料
商品名（英语：Drug nomenclature）	Danatrol, Danocrine, Danol, Danoval, others
其他名稱	WIN-17757; 2,3-Isoxazolethisterone; 2,3-Isoxazol-17α-ethynyltestosterone; 17α-Ethynyl-17β-hydroxyandrost-4-en-[2,3-d]isoxazole
AHFS/Drugs.com	Monograph
MedlinePlus	a682599
懷孕分級	澳: D
给药途径	口服给药
藥物類別（英语：Drug class）	雄激素、同化類固醇、黄体制剂、孕激素、抗促性腺激素（英语：Antigonadotropin）、固醇類合成抑制劑（英语：Steroidogenesis inhibitor）、抗動情素藥物（英语：Antiestrogen）
ATC碼	G03XA01 (WHO)
法律規範狀態
法律規範	澳：限医生处方（S4） 加：处方药（℞-only） 英：处方药（℞-only） (POM) 美：处方药（℞-only）
藥物動力學數據
生物利用度	Saturable with dosage, higher with food intake[1]
血漿蛋白結合率	會與白蛋白（英语：human serum albumin）、SHBG, CBG結合[2][3][4]
药物代谢	肝臟（CYP3A4）[8][5][9][1][6]
代謝產物	• 2-OHM-Ethisterone[5] • Ethisterone[6][7]
生物半衰期	Acute: 3–10 hours[8][1] Chronic: 24–26 hours[8]
排泄途徑	尿、糞便[8][1]
识别信息
IUPAC命名法 (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9-trien-17-ol
CAS号	17230-88-5  Y
PubChem CID	28417
IUPHAR/BPS	6942
DrugBank	DB01406 Y
ChemSpider	26436 Y
UNII	N29QWW3BUO
KEGG	D00289 Y
ChEBI	CHEBI:4315 Y
ChEMBL	ChEMBL1479 Y
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID2022880
ECHA InfoCard	100.037.503
化学信息
化学式	C22H27NO2
摩尔质量	337.463 g/mol
3D模型（JSmol（英语：JSmol））	交互式图像
SMILES C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5
InChI InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1 Y Key:POZRVZJJTULAOH-LHZXLZLDSA-N Y

達那唑具有雄性化的副作用，使其用途大受限制。常見不良反應包含痤疮、多毛症，以及聲音變低沉^[1][13]。達那唑的作用機轉複雜，同時具有弱雄激素、弱同化類固醇、弱孕激素，弱抗促性腺激素（英语：Antigonadotropin）、弱固醇類合成抑制劑（英语：steroidogenesis inhibitor），以及功能性抗動情素藥物（英语：Antiestrogen）^{[4][9][14][9][14][15]}。

達那唑發現於1963年，並於1971年應用於醫學^{[9][16][17][18]}。隨著副作用更少的性腺激素釋放素類似物（英语：gonadotropin-releasing hormone analogue）應用逐漸廣泛，達那唑在治療子宮內膜異位症的角色已被前者所取代^[3]。

參考文獻

1. 存档副本 (PDF). [2019-10-09]. （原始内容存档 (PDF)于2021-04-02）.
2. J.P. Griffin; P.F. D'Arcy. A Manual of Adverse Drug Interactions. Elsevier. 17 November 1997: 194– [2019-10-09]. ISBN 978-0-08-052583-9. （原始内容存档于2021-08-28）.
3. Eberhard Nieschlag; Hermann M. Behre; Susan Nieschlag. Andrology: Male Reproductive Health and Dysfunction. Springer Science & Business Media. 13 January 2010: 426–428. ISBN 978-3-540-78355-8.
4. Eric J. Thomas; John Rock. Modern Approaches to Endometriosis. Springer Science & Business Media. 6 December 2012: 239–256 [2019-10-09]. ISBN 978-94-011-3864-2. （原始内容存档于2020-01-10）.
5. Thomas L. Lemke; David A. Williams. Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. 24 January 2012: 1361– [2019-10-09]. ISBN 978-1-60913-345-0. （原始内容存档于2020-01-10）.
6. Florencio Zaragoza Dörwald. Lead Optimization for Medicinal Chemists: Pharmacokinetic Properties of Functional Groups and Organic Compounds. John Wiley & Sons. 4 February 2013: 485– [2019-10-09]. ISBN 978-3-527-64565-7. （原始内容存档于2020-01-09）.
7. Robert J. Kurman. Blaustein's Pathology of the Female Genital Tract. Springer Science & Business Media. 17 April 2013: 390– [2019-10-09]. ISBN 978-1-4757-3889-6. （原始内容存档于2020-01-10）.
8. Brayfield, A (编). Danazol. Martindale: The Complete Drug Reference. Pharmaceutical Press. 30 October 2013 [1 April 2014]. （原始内容存档于2021-08-28）.
9. Howard W. Jones; John A. Rock. Te Linde's Operative Gynecology. Wolters Kluwer Health. 10 July 2015: 1327–1330 [2019-10-09]. ISBN 978-1-4963-1521-2. （原始内容存档于2020-01-10）. 引用错误：带有name属性“JonesRock2015”的<ref>标签用不同内容定义了多次
10. J. Elks. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014: 345–. ISBN 978-1-4757-2085-3.
11. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000: 293– [2019-10-09]. ISBN 978-3-88763-075-1. （原始内容存档于2020-01-10）.
12. I.K. Morton; Judith M. Hall. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. 6 December 2012: 91–. ISBN 978-94-011-4439-1.
13. Selak V, Farquhar C, Prentice A, Singla A. Farquhar C , 编. Danazol for pelvic pain associated with endometriosis. Cochrane Database of Systematic Reviews. 2007, (4): CD000068. PMID 17943735. doi:10.1002/14651858.CD000068.pub2.
14. Aurel Lupulescu. Hormones and Vitamins in Cancer Treatment. CRC Press. 24 October 1990: 103– [2019-10-09]. ISBN 978-0-8493-5973-6. （原始内容存档于2020-01-10）.
15. Albert Altchek; Liane Deligdisch; Nathan Kase. Diagnosis and Management of Ovarian Disorders. Academic Press. 4 September 2003: 376– [2019-10-09]. ISBN 978-0-08-049451-7. （原始内容存档于2020-01-09）.
16. G.P. Ellis and G.B. Ellis, doi:10.1016/S0079-6468(08)70187-5 (1979),  pp. 126, note 158, 130, notes 1513, 2369, citing doi:10.1021/jm00299a034
17. Alan N. Elias; Grant Gwinup. Hirsutism. Praeger. 1 January 1983: 70 [2019-10-09]. （原始内容存档于2017-03-28）.
18. Dmowski WP, Scholer HF, Mahesh VB, Greenblatt RB. Danazol--a synthetic steroid derivative with interesting physiologic properties. Fertil. Steril. 1971, 22 (1): 9–18. PMID 5538758. doi:10.1016/S0015-0282(16)37981-X.

延伸閱讀

• Dmowski WP. Endocrine properties and clinical application of danazol. Fertil. Steril. March 1979, 31 (3): 237–51. PMID 374128. doi:10.1016/S0015-0282(16)43869-0.
• Fraser IS. Danazol--a steroid with a unique combination of actions. Scott Med J. April 1979, 24 (2): 147–50. PMID 386503. doi:10.1177/003693307902400209.
• Potts GO, Schane HP, Edelson J. Pharmacology and pharmacokinetics of danazol. Drugs. May 1980, 19 (5): 321–30. PMID 6993179. doi:10.2165/00003495-198019050-00001.
• Jenkin G. Review: The mechanism of action of danazol, a novel steroid derivative. Aust N Z J Obstet Gynaecol. May 1980, 20 (2): 113–8. PMID 6998453. doi:10.1111/j.1479-828X.1980.tb00107.x.
• Barbieri RL, Ryan KJ. Danazol: endocrine pharmacology and therapeutic applications. Am. J. Obstet. Gynecol. October 1981, 141 (4): 453–63. PMID 7025640. doi:10.1016/0002-9378(81)90611-6.
• Dmowski WP. Danazol. A synthetic steroid with diverse biologic effects. J Reprod Med. January 1990, 35 (1 Suppl): 69–74; discussion 74–5. PMID 2404115.
• Barbieri RL. Danazol: molecular, endocrine, and clinical pharmacology. Prog. Clin. Biol. Res. 1990, 323: 241–52. PMID 2406750.
• Hughes E, Brown J, Tiffin G, Vandekerckhove P. Danazol for unexplained subfertility. Cochrane Database Syst Rev. January 2007, (1): CD000069. PMID 17253444. doi:10.1002/14651858.CD000069.pub2.
• Beaumont H, Augood C, Duckitt K, Lethaby A. Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev. July 2007, (3): CD001017. PMID 17636649. doi:10.1002/14651858.CD001017.pub2.
• Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev. October 2007, (4): CD000068. PMID 17943735. doi:10.1002/14651858.CD000068.pub2.
• Craig TJ. Appraisal of danazol prophylaxis for hereditary angioedema. Allergy Asthma Proc. 2008, 29 (3): 225–31. PMID 18387221. doi:10.2500/aap.2008.29.3107.
• Ke LQ, Yang K, Li J, Li CM. Danazol for uterine fibroids. Cochrane Database Syst Rev. July 2009, (3): CD007692. PMID 19588442. doi:10.1002/14651858.CD007692.pub2.
• Letchumanan P, Thumboo J. Danazol in the treatment of systemic lupus erythematosus: a qualitative systematic review. Semin. Arthritis Rheum. February 2011, 40 (4): 298–306. PMID 20541792. doi:10.1016/j.semarthrit.2010.03.005.